Skip to content


Illumina, IDT Partner on NGS Multiplexing & Exome Enrichment

Leaders in NGS and oligo manufacturing will optimize NGS library multiplexing and co-market exome enrichment methods

Illumina, IDT Partner on NGS Multiplexing & Exome Enrichment
May 26, 2017

Illumina today announced an expanded partnership with Integrated DNA Technologies (IDT) to develop advanced solutions for next-generation sequencing (NGS) library preparation multiplexing and a co-marketing agreement linking Illumina library prep with the IDT Exome Enrichment.

A key component of the partnership is the co-development of a new portfolio of adapter indexes for NGS multiplexing, leveraging IDT’s industry-leading capabilities for the manufacture of high quality and complex oligos. The proprietary index kits will be compatible with Illumina library prep products and next-generation sequencers and are highly optimized for use on platforms with Illumina’s two-channel chemistry and patterned flow cells such as the NovaSeqTM Series. The new kits extend the number of Unique Dual Indexes (UDI) from 8 UDI to 24. The new 24 UDI kits can be ordered now and are expected to ship starting in August 2017.  The companies intend to further expand to 96 UDI kits in Q4 of 2017.

Further, the optimized index codes will be available now via IDT for incorporation into custom third party NGS library prep adapter sets.

Within the partnership, the companies will also begin to co-market an Exome Enrichment Library Preparation solution by pairing the widely adopted Illumina TruSeq® and Nextera® Library Preparation and Index Kits with the IDT xGen® Exome Research Panel. The combined offering will give customers access to a flexible, high-quality, complete solution for whole exome sequencing.  

“We look forward to strengthening our relationship with IDT so that we can better serve all NGS customers,” said Susan Tousi, Senior Vice President of Product Development at Illumina. “Our work with IDT will help us to enhance the suite of library prep offerings and multiplexing capabilities available to users of Illumina sequencing platforms. IDT is the optimal partner for this program because of their advanced nucleic acid synthesis capabilities.”

“We are very excited to expand our partnership with Illumina through both the adapter co-development effort and whole exome co-marketing activities,” said Trey Martin, Chief Operating Officer at IDT, “Both companies are committed to working together to deliver robust, high-quality NGS solutions to our customers and enable researchers to increase their discovery power. This relationship further exemplifies IDT’s longstanding commitment to delivering high quality genomic solutions to our customers and partners.”

Recent Articles

Alt text for article
Illumina @ A Glance
Alt text for article
Chinese Collaboration to Develop Cancer Tests on Illumina System
Alt text for article
Driving Insights Through Microbiome Profiling